Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Cancer, Ovarian Cancer, Solid Tumor

In brief

This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.

Key facts

Study ID

NCT00753740

Run by

NewLink Genetics Corporation

People needed

0

Starts

2008-09-01

Expected to finish

2010-05-01

Last updated by the study team

2020-06-12

Who can join

Age: 18 and older, up to 78. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois — Decatur, Illinois, United States
• University of Minnesota Medical Center — Minneapolis, Minnesota, United States
• Schwartz Gynecologic Onclology, PLLC — Brightwaters, New York, United States
• Gabrail Cancer Center — Canton, Ohio, United States
• Chattanooga GYN Oncology — Chattanooga, Tennessee, United States
• The Methodist Hospital — Houston, Texas, United States
• Riverside Gynecology & Oncology — Newport News, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.